熱門資訊> 正文
Xenetic Biosciences报告第一季度业绩
2025-05-14 20:21
- Xenetic Biosciences press release (NASDAQ:XBIO): Q1 Net loss was approximately $0.9 million.
- Revenue increased by approximately $0.1 million, or 16.1%, to approximately $0.6 million during the three months ended March 31, 2025 from approximately $0.5 million in the comparable quarter in 2024.
- The Company ended the quarter with approximately $5.2 million of cash.
More on Xenetic Biosciences
- Seeking Alpha’s Quant Rating on Xenetic Biosciences
- Historical earnings data for Xenetic Biosciences
- Financial information for Xenetic Biosciences
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
